Basel, December 9, 2020 — Novartis today announced new Kisqali® (ribociclib) data demonstrating consistent efficacy benefit with Kisqali plus endocrine therapy across the main intrinsic subtypes of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer. The largest biomarker analysis of efficacy in intrinsic subtypes evaluated whether there was a correlation between these subtypes and efficacy outcomes in patients treated with Kisqali across the three Phase III MONALEESA trials1. The findings will be presented in an oral presentation at the 2020 San Antonio Breast Cancer Virtual Symposium.

Here is the original post:
Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer

Global News Feed Comments Off on Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer | December 9th, 2020

KIRKLAND, QUEBEC, CANADA and MAINZ, GERMANY, December 9, 2020 (GLOBE NEWSWIRE) — Pfizer Canada and BioNTech SE (Nasdaq: BNTX) today announced that Health Canada has granted Authorization under Interim Order for the emergency use of their mRNA COVID-19 vaccine (BNT162b2). The distribution of the vaccine in Canada will be prioritized according to the populations identified in guidance from the National Advisory Committee on Immunizations (NACI). BioNTech will hold the regulatory approval in Canada, while Pfizer Canada will have the commercialization rights.

Go here to see the original:
Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19

Global News Feed Comments Off on Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19 | December 9th, 2020

Paris, December 09, 2020, 6pm CET

See the original post:
AB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer

Global News Feed Comments Off on AB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer | December 9th, 2020

Less than two months after Peter Kolchinsky and Raj Shah announced a new $461 million fund, the partners at RA Capital Management appear to have made another investment.

RA is headlining a $45 million Series A round for the Oxford, UK-based biotech PepGen, which focuses on severe neuromuscular diseases like Duchenne muscular dystrophy. The company will use the funding to advance a slate of what theyre calling cell-penetrating peptides combined with some of their proprietary conjugates into the clinic.

We believe PepGens PPMOs have enormous potential for the treatment of severe neuromuscular and cardiac disorders, RA venture partner Ramin Farzaneh-Far told Endpoints News in an email. The financing reflects our confidence, and that of our syndicate partners, in the technology.

Oxford Sciences Innovation, PepGens seed investor, also participated in the round, as well as the University of Oxford and CureDuchenne Ventures. Wednesdays cash will also allow PepGen to build out a corporate team in the new Boston headquarters and expand the R&D hub in the UK, Farzaneh-Far said.

The move from RA comes shortly after Shah told Endpoints News in October that the cash for its Nexus I life sciences fund, roughly $300 million, was churned through at a relatively rapid pace. In just 15 months of investment, RA had spent about 80% of their fund, which prompted the Nexus II raise.

Though the new fund built off largely the first, the cash pools remain separate. Farzaneh-Far declined to comment to which Nexus fund Wednesdays investment belonged.

PepGen itself was spun out of Oxford in 2018 in order to further develop the peptides at the heart of its research. The biotech says that the cell-penetrating nature of the peptides, when conjugated with phosphorodiamidate morpholino oligomers or PPMOs, could allow for enhanced delivery of oligonucleotides to key tissues, while also improving safety compared to other medicines.

Specifically, PepGen is hoping to leapfrog the exon-skipping approaches already available in order to restore dystrophin expression in DMD patients, CEO and co-founder Caroline Godfrey said in a statement.

One of the areas where PepGen says its programs are beneficial is in the cardiovascular comorbidities that often accompany DMD. Because the peptides can penetrate cells, the company says its drug candidates strongly distribute to cardiac tissue.

With the recent approvals of treatments that generate small increases in dystrophin in skeletal muscle, patients may be ambulating and living longer, but this in turn is expected to shift the burden of morbidity and mortality towards an epidemic of heart disease, which is not adequately addressed by current DMD therapies, Farzaneh-Far said in an earlier statement.

This past summer, the FDA green-lit the third DMD drug when Japanese developer NS Pharma gained an accelerated approval for viltolarsen. That followed a wild back-and-forth between regulators and Sarepta, who originally rejected their DMD candidate in August 2019 but reversed course later that year.

The agency, however, still doesnt have full efficacy data on any of the three approved DMD drugs, as the OKs were all based on the same disease biomarker.

See original here:
RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and other similar diseases - Endpoints News

Cardiac Stem Cells Comments Off on RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and other similar diseases – Endpoints News | December 9th, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from Group C of its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy (bb1111) for adult and adolescent patients with sickle cell disease (SCD) show a complete elimination of severe VOEs and VOEs between six and 24 months of follow-up. These data are being presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020.

Now with more than two years of data, we continue to observe promising results in our studies of LentiGlobin for SCD that further illustrate its potential to eliminate the symptoms and devastating complications of sickle cell disease. Consistently achieving the complete resolution of severe vaso-occlusive events (VOEs) and VOEs between Month 6 and Month 24 follow-up is unprecedented other than with allogeneic stem cell transplantation. Importantly, our data show the potential for LentiGlobin for SCD to produce fundamentally disease-modifying effects with sustained pancellular distribution of gene therapy-derived anti-sickling HbAT87Q and improvement of key markers of hemolysis that approach normal levels, said David Davidson, M.D., chief medical officer, bluebird bio. In addition to these clinical outcomes, for the first time with a gene therapy we now have patient-reported outcomes through the validated PROMIS-57 tool, showing reduction in pain intensity at 12 months after treatment with LentiGlobin for SCD. These results provide insight into the potential real-life impact LentiGlobin for SCD may offer patients.

SCD is a serious, progressive and debilitating genetic disease. In the U.S., the median age of death for someone with sickle cell disease is 43 46 years. SCD is caused by a mutation in the -globin gene that leads to the production of abnormal sickle hemoglobin (HbS). HbS causes red blood cells to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and unpredictable, painful VOEs.

In the HGB-206 study of LentiGlobin for SCD, VOEs are defined as episodes of acute pain with no medically determined cause other than a vaso-occlusion, lasting more than two hours and severe enough to require care at a medical facility. This includes acute episodes of pain, acute chest syndrome (ACS), acute hepatic sequestration and acute splenic sequestration. A severe VOE requires a 24-hour hospital stay or emergency room visit or at least two visits to a hospital or emergency room over a 72-hour period, with both visits requiring intravenous treatment.

LentiGlobin for SCD was designed to add functional copies of a modified form of the -globin gene (A-T87Q-globin gene) into a patients own hematopoietic (blood) stem cells (HSCs). Once patients have the A-T87Q-globin gene, their red blood cells can produce anti-sickling hemoglobin (HbAT87Q) that decreases the proportion of HbS, with the goal of reducing sickled red blood cells, hemolysis and other complications.

As a hematologist, I regularly see the debilitating effects of pain events caused by sickle cell disease. Pain has an overwhelmingly negative impact on many facets of my patients lives and can lead to prolonged hospitalizations, said presenting study author Alexis A. Thompson, M.D., professor of pediatrics at Northwestern University Feinberg School of Medicine and head of hematology at Ann and Robert H. Lurie Childrens Hospital of Chicago. The results observed with LentiGlobin gene therapy for SCD include the complete elimination of severe vaso-occlusive pain episodes, which is certainly clinically meaningful, but also for the first time, we have documented patients reporting that they are experiencing improved quality of life. This degree of early clinical benefit is extraordinarily rewarding to observe as a provider."

As of the data cut-off date of August 20, 2020, a total of 44 patients have been treated with LentiGlobin for SCD in the HGB-205 (n=3) and HGB-206 (n=41) clinical studies. The HGB-206 total includes: Groups A (n=7), B (n=2) and C (n=32).

HGB-206: Group C Updated Efficacy Results

The 32 patients treated with LentiGlobin for SCD gene therapy in Group C of HGB-206 had up to 30.9 months of follow-up (median of 13.0; min-max: 1.1 30.9 months).

In patients with six or more months of follow-up whose hemoglobin fractions were available (n=22), median levels of gene therapy-derived anti-sickling hemoglobin, HbAT87Q, were maintained with HbAT87Q contributing at least 40% of total hemoglobin at Month 6. At last visit reported, total hemoglobin ranged from 9.6 15.1 g/dL and HbAT87Q levels ranged from 2.7 8.9 g/dL. At Month 6, the production of HbAT87Q was associated with a reduction in the proportion of HbS in total hemoglobin; median HbS was 50% and remained less than 60% at all follow-up timepoints. All patients in Group C were able to stop regular blood transfusions by three months post-treatment and remain off transfusions as of the data cut-off.

Nineteen patients treated in Group C had a history of severe VOEs, defined as at least four severe VOEs in the 24 months prior to informed consent (annualized rate of severe VOE min-max: 2.0 10.5 events) and at least six months follow-up after treatment with LentiGlobin for SCD. There have been no reports of severe VOEs in these Group C patients following treatment with LentiGlobin for SCD. In addition, all 19 patients had a complete resolution of VOEs after Month 6.

Hemolysis Markers

In SCD, red blood cells become sickled and fragile, rupturing more easily than healthy red blood cells. The breakdown of red blood cells, called hemolysis, occurs normally in the body. However, in sickle cell disease, hemolysis happens too quickly due to the fragility of the red blood cells, which results in hemolytic anemia.

Patients treated with LentiGlobin for SCD in Group C demonstrated near-normal levels in key markers of hemolysis, which are indicators of the health of red blood cells. Lab results assessing these indicators were available for the majority of the 25 patients with 6 months of follow-up.

The medians for reticulocyte counts (n=23), lactate dehydrogenase (LDH) levels (n=21) and total bilirubin (n=24) continued to improve compared to screening values and stabilized by Month 6. In patients with Month 24 data (n=7), these values approached the upper limit of normal by Month 24. These results continue to suggest that treatment with LentiGlobin for SCD may improve biological markers to near-normal levels for SCD.

Pancellularity

As previously reported, assays were developed by bluebird bio to enable the detection of HbAT87Q and HbS protein in individual red blood cells, as well as to assess if HbAT87Q was pancellular, or present throughout all of a patients red blood cells. In 25 patients with at least six months of follow-up, on average, more than 80% of red blood cells contained HbAT87Q, suggesting near-complete pancellularity of HbAT87Q distribution and with pancellularity further increasing over time.

HGB-206: Improvements in Health-Related Quality of Life

Health-related quality of life (HRQoL) findings in Group C patients treated with LentiGlobin for SCD in the HGB-206 study were generated using the Patient Reported Outcomes Measurement Information System 57 (PROMIS-57), a validated instrument in SCD.

Data assessing pain intensity experienced by nine Group C patients were analyzed according to baseline pain intensity scores relative to the general population normative value: 2.6 on a scale of 0-10, where 10 equals the most intense pain. Data were assessed at baseline, Month 6 and Month 12.

Of the five patients with baseline scores worse than the population normative value average, four demonstrated clinically meaningful reductions in pain intensity at Month 12; the group had a mean score of 6.0 at baseline and a mean score of 2.4 at Month 12. Of the four patients with better than or near population normative values at baseline, two reported improvement and two remained stable with a mean score of 2.3 at baseline and 0.8 at Month 12.

HGB-206: Group C Safety Results

As of August 20, 2020, the safety data from Group C patients in HGB-206 remain generally consistent with the known side effects of hematopoietic stem cell collection and myeloablative single-agent busulfan conditioning, as well as underlying SCD. One non-serious, Grade 2 adverse event (AE) of febrile neutropenia was considered related to LentiGlobin for SCD. There were no serious AEs related to LentiGlobin for SCD.

One patient with significant baseline SCD-related and cardiopulmonary disease died 20 months post-treatment; the treating physician and an independent monitoring committee agreed his death was unlikely related to LentiGlobin for SCD and that SCD-related cardiac and pulmonary disease contributed.

LentiGlobin for SCD Data at ASH

The presentation of HGB-206 Group C results and patient reported outcomes research are now available on demand on the ASH conference website:

About HGB-206

HGB-206 is an ongoing, Phase 1/2 open-label study designed to evaluate the efficacy and safety of LentiGlobin gene therapy for sickle cell disease (SCD) that includes three treatment cohorts: Groups A (n=7), B (n=2) and C (n=32). A refined manufacturing process designed to increase vector copy number (VCN) and further protocol refinements made to improve engraftment potential of gene-modified stem cells were used for Group C. Group C patients also received LentiGlobin for SCD made from HSCs collected from peripheral blood after mobilization with plerixafor, rather than via bone marrow harvest, which was used in Groups A and B of HGB-206.

About LentiGlobin for SCD (bb1111)

LentiGlobin gene therapy for sickle cell disease (bb1111) is an investigational treatment being studied as a potential treatment for SCD. bluebird bios clinical development program for LentiGlobin for SCD includes the completed Phase 1/2 HGB-205 study, the ongoing Phase 1/2 HGB-206 study, and the ongoing Phase 3 HGB-210 study.

The U.S. Food and Drug Administration granted orphan drug designation, fast track designation, regenerative medicine advanced therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for SCD.

LentiGlobin for SCD received orphan medicinal product designation from the European Commission for the treatment of SCD, and Priority Medicines (PRIME) eligibility by the European Medicines Agency (EMA) in September 2020.

bluebird bio is conducting a long-term safety and efficacy follow-up study (LTF-307) for people who have participated in bluebird bio-sponsored clinical studies of LentiGlobin for SCD. For more information visit: https://www.bluebirdbio.com/our-science/clinical-trials or clinicaltrials.gov and use identifier NCT04628585 for LTF-307.

LentiGlobin for SCD is investigational and has not been approved in any geography.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

LentiGlobin and bluebird bio are trademarks of bluebird bio, Inc.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: regarding the potential for LentiGlobin for Sickle Cell Disease to treat SCD; the risk that the efficacy and safety results from our prior and ongoing clinical trials will not continue or be repeated in our ongoing or planned clinical trials; the risk that the current or planned clinical trials of our product candidates will be insufficient to support regulatory submissions or marketing approval in the United States and European Union; the risk that regulatory authorities will require additional information regarding our product candidates, resulting in delay to our anticipated timelines for regulatory submissions, including our applications for marketing approval; and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Read more:
Treatment with Investigational LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe...

Cardiac Stem Cells Comments Off on Treatment with Investigational LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe… | December 8th, 2020

It sounds too good to be true - and it is. But Jose Bianco Moreira and the CERG research group at the Norwegian University of Science and Technology (NTNU) are convinced that some of the positive health effects of physical exercise can be achieved using gene therapy and medication.

"We're not talking about healthy people and everyone who can exercise. They still have to train, of course," says Moreira. He and his colleagues at NTNU's Department of Circulation and Medical Imaging are studying the effect of exercise on our cells.

"But some people can't train, or only in a limited way. This could include individuals who've been in accidents, who are in wheelchairs, or who have diseases that prevent the possibility of physical expression. We want to create hope for these folks."

"A small group of healthy people out there also obtain very little effect from physical exercise - so-called low responders - and would benefit from a method that worked at the cellular level," says Moreira.

A lot of research confirms the health benefits of physical exercise, but we know far less about what happens in the cells that provides the positive effects.

"International research in this field is brand new. We've barely scratched the surface," says the researcher.

"We think increasing our knowledge about what happens at the cellular level will be important for discovering medications and treatments for heart disease. My group studies genes, proteins and mitochondria that produce energy and are key for chemical processes in the cells."

Moreira believes that gene therapy is the most effective method for reproducing the health benefits we normally get through physical exercise.

A medicine that uses gene therapy is already in use for spinal muscle atrophy, a serious disease that leads to muscle wasting. The drug uses a harmless virus to deliver a copy that replaces the damaged motor neuron network in patients.

This form of therapy can inhibit or enhance the expression of a gene. This is a very expensive medicine and has not been tried for heart disease, for example.

Moreira believes CRISPR will be the future go-to gene therapy method. He believes this method of editing the genes will revolutionize a lot of disease treatments.

"CRISPR is easier to use, faster and cheaper than today's gene therapy, which only attenuates or enhances the expression of a gene. CRISPR's potential is almost limitless. It can alter the gene itself. The parts of the gene that don't work properly are replaced with well-functioning parts."

Experiments on rats and mice have shown that the method works. Experiments have also been performed on human cells in the laboratory to confirm CRISPR's effectiveness, but it has not yet been tested on humans.

"CRISPR still has to be tested in large clinical studies. I'd be optimistic if I say gene editing will come into regular use in 10-15 years," says Moreira.

Moreira's research group has used CRISPR in its research, but the results are not yet ready for publication.

"We believe gene therapy is the most powerful method because patients don't have to take a pill every day. Usually, gene therapy changes the gene forever, perhaps with an injection or two. The challenge is to find the right gene that needs change, and an effective method to repair it," he says.

NTNU researchers are focusing on the heart. They have identified a protein that heart-diseased rats are deficit in, but which increases when the rats go through training.

"By increasing the amount of this protein through gene therapy, we've managed to strengthen the muscle cells and have replicated some of the positive effects of physical exercise," says Moreira.

Medications are another possible method of mimicking the effects of exercise. Some existing medicines might even be able to recreate some of the positive effect on the heart.

"The research now has powerful technology platforms to find possible other uses for medicines we already have. One problem, of course, is that medicine is chemistry that affects the whole body, not just the organ you want to help. Something that's good for the heart could be detrimental for the liver, for example. Compared to gene therapy, though, the potential for medications is much more limited," Moreira says.

When the research group at NTNU started their study, they had no idea which genes were affected by exercise. They performed experiments where rats with heart defects underwent training. Afterwards, the hearts were removed and examined. Then these hearts were compared with those from untrained rats with heart disease. Afterwards, the hearts of the trained and untrained rats with heart disease were compared to healthy rat hearts.

"We observed that genes were altered in the diseased hearts, but discovered that some of them were repaired in the rats that had trained. This way, we find genes that we can target. Through our measurements, we can find out exactly what training changes at the cellular level," says Moreira.

Reference: Moreira, J.B.N., Wohlwend, M. & Wislff, U. Exercise and cardiac health: physiological and molecular insights. Nat Metab. 2020;2,829839. doi:10.1038/s42255-020-0262-1

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Could Gene Therapy Be Used To Mimic the Positive Effects of Exercise? - Technology Networks

Cardiac Stem Cells Comments Off on Could Gene Therapy Be Used To Mimic the Positive Effects of Exercise? – Technology Networks | December 8th, 2020

myCare-021-04 study finds genetic signatures associated with 100% remission rate fromAML induction therapy despite presence of Monosomy 7

Read the original here:
Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7

Global News Feed Comments Off on Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7 | December 8th, 2020

myCare-021-02 study discovers patient-specific resistance mechanisms that can inform treatment planning and improve AML patient outcomes myCare-021-02 study discovers patient-specific resistance mechanisms that can inform treatment planning and improve AML patient outcomes

Read the rest here:
Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

Global News Feed Comments Off on Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies | December 8th, 2020

myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders

Originally posted here:
Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

Global News Feed Comments Off on Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy | December 8th, 2020

myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and sensitivity in predicting complete response to physician prescribed therapies for AML and MDS patients myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and sensitivity in predicting complete response to physician prescribed therapies for AML and MDS patients

See the original post here:
Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients

Global News Feed Comments Off on Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients | December 8th, 2020

AUTO3 continues to show a differentiated product profile supporting outpatient administration

More here:
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting

Global News Feed Comments Off on Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting | December 8th, 2020

Original post:
Signal Relief Patch Reviews – Pain Patch launched - Product Review by Mike Vaughn

Global News Feed Comments Off on Signal Relief Patch Reviews – Pain Patch launched – Product Review by Mike Vaughn | December 8th, 2020

Daix (France), December 7, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the publication of a scientific paper on the beneficial effects of lanifibranor on experimental advanced chronic liver disease (ACLD) by the peer-reviewed scientific journal Journal of Hepatology.

Read the original post:
Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis

Global News Feed Comments Off on Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis | December 8th, 2020

SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A. Collard, a seasoned biopharmaceutical leader with over 20 years of commercial and executive experience, to Chairman of its Board of Directors, effective January 1, 2021. Mr. Collard joined the Opiant board in 2018. Gabrielle Silver, M.D., who has served as Lead Independent Director since October, 2018, will remain an independent director on the Board and continue to be Chairman of the Nominating and Governance Committee.

Visit link:
Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors

Global News Feed Comments Off on Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors | December 8th, 2020

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a clinical update for its three most advanced TriTAC® programs. The discussion will be focused on HPN424 for the treatment of metastatic castration resistant prostate cancer, HPN536 initially in development for ovarian and pancreatic cancer and mesothelioma, and HPN217 for relapsed/refractory multiple myeloma.

The rest is here:
Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

Global News Feed Comments Off on Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020 | December 8th, 2020

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020, and provides guidance for 2021.

Originally posted here:
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021

Global News Feed Comments Off on Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021 | December 8th, 2020

BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET.

Read more here:
Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020

Global News Feed Comments Off on Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020 | December 8th, 2020

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will provide an end-of-year business update on veverimer’s development program, regulatory status and patent protection.

View original post here:
Tricida to Provide an End-of-Year Business Update

Global News Feed Comments Off on Tricida to Provide an End-of-Year Business Update | December 8th, 2020

TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Jeanne Thoma as an independent member of the company’s board of directors. Ms. Thoma is a seasoned pharmaceutical industry executive with more than 30 years of experience spanning product development and commercialization, as well as operations and supply chain management.

Read more:
Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors

Global News Feed Comments Off on Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors | December 8th, 2020

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/.

See more here:
Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference

Global News Feed Comments Off on Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference | December 8th, 2020